PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

DK-US065116

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE			Application Number	10/581,085	
STATEMENT BY APPLICANT		Filing Date	May 31, 2006		
0.7.		A LIOAN	First Named Inventor	Junko TAKAHASHI	
			Group Art Unit	1638	
(use as many sheets as necessary)		Examiner Name			
Sheet	1	of 1	Attorney Docket Number	DK-US065116	

Attorney Docket Number

			U.S. PATENT [DOCUMENTS	
Examiner Initials *	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan Passages or Relevant
	140.	Number - Kind Code ² (if known)			Figures Appear
	ļ	US- 2002/0103154-A1	08-01-2002	Dimster-Denk	
		US- 2003/0180953-A1	09-25-2003	Roemer et al.	
		US-			
		US-	•		
		US-			
	•	US-			
		US-			
		US-	taya daga da ayla da daga karaban ya mbay		
		US-			
,		US-			
		US-			
		US-			
		US-		<u> </u>	

FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns,		
Examiner Initials*	Cite No. ¹	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY		Lines, Where Relevant Passages or Relevant Figures Appear	T ₆	
		WO-03/010333-A2	02-06-2003	Awrey et al.		N/A	
		WO-03/010333-A3	02-06-2003	Awrey et al.		N/A	
-							

|--|

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-07)

Approved for use through 10/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/F	PTO		Complete if Known		
			Application Number	10/581,085	
INFORMATION	ON DIS	CLOSURE	Filing Date	May 31, 2006	
STATEMEN'	T BY A	PPLICANT	First Named Inventor	Junko TAKAHASHI	
(Heo ac man	y sheets as n	roccocany)	Art Unit	1638	
(Use as man	y sneets as n	ecessary)	Examiner Name		
Sheet 2	of	2	Attorney Docket Number	DK-US065116	

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1000	NICOLAS PAGE et al.;"A Saccharomyces cerevisiae Genome-Wide Mutant Screen for Altered Sensitivity to K1 Killer Toxin";Genetics; March 2003; Vol. 163 No. 3 pages 875-894	
		GURI GIAEVER et al.; "Genomic Profiling of drug sensitivities via induced haploinsufficiency"; Nature Genetics; March 1999; Vol. 21 No. 3 pages 278-283	
		BISWAS SUBHRAJIT et al.; "N-Acetylglucosamine-inducible CAGAP1 encodes a general amino acid permease which co-ordinates external nitrogen source response and morphogenesis in Candida albicans"; Microbiology; September 2003; Vol. 149 No. 9 pages 2597-2608	
		K.L. JENSEN-PERGAKES et al.; "Sequencing, Disruption, and Characterization of the Candida albicans Sterol Methyltransferase (ERG6) Gene: Drug Susceptibility Studies in erg6 Mutants"; Antimicrobial Agents and Chemotherapy; May 1998; Vol. 42 No. 5 pages 1160-1167	
		DAIAN E. KELLY et al.; "Genome-wide generation of yeast gene deletion strains"; Comparative and Functional Genomics; August 2001; Vol. 2 No. 4 pages 236-242	
		ELOI GARI et al.; "A Set of Vectors with a Tetracycline-Regulatable Promoter System for Modulated Gene Expression in Saccharomyces cerevisiae" Yeast; 1997; Vol. 13 No. 9 pages 837-848	
		MARIANNE D. DE BACKER et al.; "Genomic Profiling of the Response of Candida albicans to Itraconazole Treatment Using a DNA Microarray; Antimicrobial Agents and Chemotherapy; June 2001; Vol. 45 No. 6 pages 1660-1670	
	·	MARIANNE D. DE BACKER et al.; "Recent Developments in Molecular Genetics of Candida Albicans"; Annual Review of Microbiography; 2000; Vol. 54 Pages 463-498	

Examiner	·	Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:**Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.